Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Glioblastoma 101Glioma 43Brain Neoplasms 29Neuroblastoma 25Astrocytoma 19Gliosarcoma 15Sarcoma, Ewing 12Rhabdomyosarcoma 12Neoplasms 12Recurrence 11Medulloblastoma 11Oligodendroglioma 9Small Cell Lung Carcinoma 8Sarcoma 8Melanoma 7Diffuse Intrinsic Pontine Glioma 7Osteosarcoma 6Ependymoma 6Central Nervous System Neoplasms 4Rhabdoid Tumor 3Prostatic Neoplasms 3Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive 3Neoplasm Metastasis 3Lymphoma, Follicular 3Lymphoma 3Lung Neoplasms 3Ganglioneuroblastoma 3Desmoplastic Small Round Cell Tumor 3Colorectal Neoplasms 3

Interventions

Temozolomide 1Paclitaxel 1Dacarbazine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Melanoma × Temozolomide × 1 year × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡